A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

NCT01650701 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1030

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Rituximab
DRUG: Lenalidomide
DRUG: Rituximab - CHOP
DRUG: Rituximab - CVP
DRUG: Rituximab - Bendamustine

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]